businesspress24.com - Regen BioPharma Inc. Announces Preferred Stock Dividend
 

Regen BioPharma Inc. Announces Preferred Stock Dividend

ID: 1339643

(firmenpresse) - SAN DIEGO, CA -- (Marketwired) -- 02/24/15 -- Regen BioPharma Inc. (OTCBB: RGBP) announced today that its Board of Directors has declared a stock dividend to common shareholders of record as of March 10, 2015 to be paid to shareholders on or about March 20, 2015.

Common shareholders will be entitled to receive one share of Series A Preferred Stock for every 10 shares of Regen Biopharma, Inc. common Stock owned as of the Record Date.

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP). The Company is focused on identifying undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia. Regen is majority owned by Bio-Matrix Scientific Group Inc. (OTC PINK: BMSN).

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.



Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404 Phone
619-330-2328 Fax




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  VANC Pharmaceuticals Announces Low Cost Alternative Approval of 14 Products From British Columbia Ministry of Health
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Full Year 2014 on March 11th
Bereitgestellt von Benutzer: Marketwired
Datum: 24.02.2015 - 20:00 Uhr
Sprache: Deutsch
News-ID 1339643
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SAN DIEGO, CA


Phone:

Kategorie:

Drugs


Anmerkungen:


Diese Pressemitteilung wurde bisher 187 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Regen BioPharma Inc. Announces Preferred Stock Dividend
"
steht unter der journalistisch-redaktionellen Verantwortung von

Bio-Matrix Scientific Group, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Bio-Matrix Scientific Group, Inc.



 

Who is online

All members: 10 563
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 76


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.